Hyperpigmentation

 

What is hyperpigmentation?

Hyperpigmentation is a darkening of the skin. This darkening of the skin may be generalized (happen all over) or localized, causing blotchy skin. It may be related to a phototoxic reaction in which areas exposed to light could have a golden brown or gray color.

What causes hyperpigmentation?

Some chemotherapy agents can cause hyperpigmentation. The cause of this side effect is currently unknown but may involve direct toxicity, stimulation of melanocytes (cells in skin responsible for skin color), and/or inflammation. Hyperpigmentation often appears 2 to 3 weeks after chemotherapy treatment begins and goes away as new skin cells replace the dead cells at approximately 10 to 12 weeks after treatment is over. However, this darkening may occasionally be permanent.

Chemotherapy drugs associated with temporary hyperpigmentation include:

  • Alkeran® (melphalan)
  • Myleran® (busulfan)
  • Cytoxan® (cyclophosphamide)
  • 5-FU (5-fluorouacil)
  • Adriamycin® (doxorubicin)
  • DaunoXome® (liposomal daunorubicin)
  • Blenoxane® (bleomycin)
  • Cosmegen® (dactinomycin)
  • BCNU (topical)

What are the symptoms of hyperpigmentation?

Hyperpigmentation from chemotherapy drugs may be generalized or it may occur in specific areas, such as:

  • Around the joints
  • Under the nails
  • In the mouth
  • Along the vein used to infuse chemotherapy
  • Under areas compressed by tape or dressings
  • In the hair (horizontal bands in light haired individuals)

How is hyperpigmentation treated?

At this time, there is no treatment for hyperpigmentation.

This content was last modified on May 01, 2008 .
Latest Cancer News
ACOG Updates Cervical Cancer Screening Guidelines

November 20, 2009 — The American College of Obstetricians and Gynecologists (ACOG) has revised its cervical cancer screening recommendations: the organization now recommends that women begin screening at the age of 21 and receive screening at less frequent intervals. These recommendations will be published in the December 2009 issue of Obstetrics and Gynecology.

New Velcade®-melphalan Transplant Regimen for Multiple Myeloma

November 20, 2009 — Researchers from France have reported encouraging results with adding Velcade® (bortezomib) to high-dose melphalan followed by autologus stem cell infusion for initial treatment of patients with newly diagnosed multiple myeloma. The details of this Phase II study appeared in an early online publication in Blood on November 2, 2009.

Folic Acid May Be Beneficial in Patients with Recurrent Colorectal Adenoma Who Are Folate Deficient

November 20, 2009 — Researchers affiliated with the Health Professional Follow-Up Study and the Nurses’ Health Study have reported that folic acid supplementation in patients with recurrent colorectal adenoma was not protective or harmful in most patients. However, patients who were folate deficient had a significant 39% decrease in adenoma recurrence. The details of this study appeared in an early online publication on October 28, 2009 in the American Journal of Clinical Nutrition.

Select news items provided by Reuters Health